KR20070091662A - 다발성 경화증 치료용 클라드리빈 치료법 - Google Patents

다발성 경화증 치료용 클라드리빈 치료법 Download PDF

Info

Publication number
KR20070091662A
KR20070091662A KR1020077016508A KR20077016508A KR20070091662A KR 20070091662 A KR20070091662 A KR 20070091662A KR 1020077016508 A KR1020077016508 A KR 1020077016508A KR 20077016508 A KR20077016508 A KR 20077016508A KR 20070091662 A KR20070091662 A KR 20070091662A
Authority
KR
South Korea
Prior art keywords
cladribine
months
period
multiple sclerosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077016508A
Other languages
English (en)
Korean (ko)
Inventor
지엠피에로 데 루카
Original Assignee
라보라뚜와르 세로노 에스. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070091662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 라보라뚜와르 세로노 에스. 에이. filed Critical 라보라뚜와르 세로노 에스. 에이.
Publication of KR20070091662A publication Critical patent/KR20070091662A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020077016508A 2004-12-22 2005-12-20 다발성 경화증 치료용 클라드리빈 치료법 Ceased KR20070091662A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
US60/638,669 2004-12-22
EP04106909.7 2004-12-22
EP04106909 2004-12-22

Publications (1)

Publication Number Publication Date
KR20070091662A true KR20070091662A (ko) 2007-09-11

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077016508A Ceased KR20070091662A (ko) 2004-12-22 2005-12-20 다발성 경화증 치료용 클라드리빈 치료법

Country Status (25)

Country Link
US (2) US7713947B2 (enExample)
EP (7) EP2805723B1 (enExample)
JP (7) JP5795456B2 (enExample)
KR (1) KR20070091662A (enExample)
AR (1) AR052830A1 (enExample)
AU (2) AU2005318190B2 (enExample)
BR (1) BRPI0517132B8 (enExample)
CA (2) CA2588966C (enExample)
CY (3) CY1112614T1 (enExample)
DK (3) DK2805723T3 (enExample)
EA (1) EA015799B1 (enExample)
ES (2) ES2921858T3 (enExample)
FI (1) FI4070800T3 (enExample)
FR (1) FR18C1008I2 (enExample)
HR (1) HRP20120228T1 (enExample)
HU (3) HUE070333T2 (enExample)
IL (2) IL183930A0 (enExample)
LT (3) LT3332789T (enExample)
LU (1) LUC00064I2 (enExample)
MX (1) MX2007007610A (enExample)
NO (1) NO20073813L (enExample)
PL (4) PL4070800T3 (enExample)
SG (1) SG160391A1 (enExample)
SI (3) SI2805723T1 (enExample)
WO (1) WO2006067141A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200090824A (ko) * 2017-11-24 2020-07-29 메르크 파텐트 게엠베하 진행 형태의 다발성 경화증의 치료에서 사용을 위한 클라드리빈 용법
US12377056B2 (en) 2006-05-24 2025-08-05 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
CA2208484C (en) 1994-12-22 2008-09-23 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP4757632B2 (ja) 2002-09-25 2011-08-24 ブリガム ヤング ユニバーシティー ２’−デオキシグアノシンから２−クロロ−２’−デオキシアデノシンを調製する方法
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004075903A1 (en) * 2003-02-25 2004-09-10 Applied Research Systems Ars Holding N.V. Combined use of ribavirin and interferon beta in demyelinating diseases
CA2520522C (en) 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
US7888328B2 (en) 2003-03-28 2011-02-15 Ares Trading S.A. Oral formulations of cladribine
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377056B2 (en) 2006-05-24 2025-08-05 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
KR20200090824A (ko) * 2017-11-24 2020-07-29 메르크 파텐트 게엠베하 진행 형태의 다발성 경화증의 치료에서 사용을 위한 클라드리빈 용법
US12268703B2 (en) 2017-11-24 2025-04-08 Ares Trading S.A. Cladribine regimen for treating progressive forms of multiple sclerosis

Also Published As

Publication number Publication date
CA3087419A1 (en) 2006-06-29
BRPI0517132B8 (pt) 2021-05-25
LTC2805723I2 (lt) 2022-04-25
EP4523753A2 (en) 2025-03-19
DK2805723T3 (da) 2018-01-29
JP2008524313A (ja) 2008-07-10
PL4070800T3 (pl) 2025-03-10
IL212421A0 (en) 2011-06-30
CA2588966A1 (en) 2006-06-29
LUC00064I1 (enExample) 2018-02-14
CY1112614T1 (el) 2016-02-10
JP2018165271A (ja) 2018-10-25
EP1827461A1 (en) 2007-09-05
ES3007339T3 (en) 2025-03-19
LTPA2018503I1 (lt) 2018-03-12
EP4070800A1 (en) 2022-10-12
JP2017101061A (ja) 2017-06-08
EA015799B1 (ru) 2011-12-30
PL3332789T3 (pl) 2022-08-22
EP1827461B1 (en) 2012-02-29
US20090081163A1 (en) 2009-03-26
EA200701221A1 (ru) 2008-02-28
JP2020193206A (ja) 2020-12-03
IL183930A0 (en) 2007-10-31
NO20073813L (no) 2007-09-21
JP6430554B2 (ja) 2018-11-28
US20100203017A1 (en) 2010-08-12
CA3087419C (en) 2023-03-07
HRP20120228T1 (hr) 2012-04-30
EP2805723B1 (en) 2018-01-17
EP3332789B1 (en) 2022-04-06
CY2018006I1 (el) 2018-06-27
HUS1800009I1 (hu) 2018-05-02
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
ES2921858T3 (es) 2022-09-01
JP5795456B2 (ja) 2015-10-14
CY2018006I2 (el) 2018-06-27
PL1827461T3 (pl) 2012-07-31
FR18C1008I2 (fr) 2019-03-01
JP6092945B2 (ja) 2017-03-08
JP5908863B2 (ja) 2016-04-26
AR052830A1 (es) 2007-04-04
EP3332789A1 (en) 2018-06-13
BRPI0517132A (pt) 2008-09-30
EP2263678B1 (en) 2014-06-11
EP4523753A3 (en) 2025-05-28
EP2275110A3 (en) 2011-04-27
AU2011200768B2 (en) 2012-09-13
IL212421A (en) 2014-01-30
LT4070800T (lt) 2025-01-10
LT3332789T (lt) 2022-07-25
SI2805723T1 (en) 2018-02-28
LUC00064I2 (enExample) 2018-03-28
FR18C1008I1 (enExample) 2018-03-30
SI3332789T1 (sl) 2022-08-31
JP2016138128A (ja) 2016-08-04
JP2015180685A (ja) 2015-10-15
EP4070800B1 (en) 2024-10-16
EP2275110A2 (en) 2011-01-19
WO2006067141A1 (en) 2006-06-29
EP2805723A1 (en) 2014-11-26
AU2005318190A1 (en) 2006-06-29
HUE059133T2 (hu) 2022-10-28
CY1119790T1 (el) 2018-06-27
EP2263678A3 (en) 2011-04-27
AU2011200768A1 (en) 2011-03-17
US7713947B2 (en) 2010-05-11
EP2275110B1 (en) 2013-07-10
JP6290962B2 (ja) 2018-03-07
SI4070800T1 (sl) 2025-03-31
JP2013216664A (ja) 2013-10-24
AU2005318190B2 (en) 2010-11-25
MX2007007610A (es) 2007-08-03
FI4070800T3 (fi) 2025-01-14
PL2805723T3 (pl) 2018-04-30
SG160391A1 (en) 2010-04-29
CA2588966C (en) 2020-07-21
BRPI0517132B1 (pt) 2020-02-18
US8377903B2 (en) 2013-02-19
HUE070333T2 (hu) 2025-05-28
EP2263678A2 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
EP2026832B1 (en) Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis
JP6430554B2 (ja) 多発性硬化症を治療するためのクラドリビン投薬計画
HK40083827A (en) Cladribine regimen for treating multiple sclerosis
HK40083827B (en) Cladribine regimen for treating multiple sclerosis
HUE035859T2 (en) Cladribine regimen for treating multiple sclerosis
CN101090726A (zh) 治疗多发性硬化的克拉屈滨方案
HK1110517A (en) Cladribine regimen for treating multiple sclerosis
HK1127753B (en) Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130215

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130830

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130215

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130925

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130830

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2013101006939

Request date: 20130925

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20130925

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20130925

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130415

Patent event code: PB09011R02I

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20131106

Patent event code: PE09021S02D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20130925

Effective date: 20150724

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20150724

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20130925

Decision date: 20150724

Appeal identifier: 2013101006939